Construction and empirical study of blood pressure management program for acute stroke inpatients based on wearable devices

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200057564

Enrollment

Unknown

Registered

2022-03-15

Start date

2022-03-20

Completion date

Unknown

Last updated

2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

Intervention group:Use wearable devices to manage blood pressure

Control group:Manage blood pressure with an electronic sphygmomanometer

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >=18 years old; 2. Cerebrovascular disease within 72 hours of onset (both ischemic stroke and spontaneous intracerebral hemorrhage; Acute cerebrovascular events require MRI or CT confirmation; If the exact onset time is uncertain, the last known onset time is taken; Patients with intracranial hemorrhage who took antiplatelet or anticoagulant drugs at the same time were allowed to be enrolled; Patients with first or multiple strokes can enter); 3. Clear mind, no cognitive dysfunction (ATM>=8 points), communication barrier-free; 4. Systolic blood pressure >=150mmHg at admission (mean value of two measurements in supine position, interval of more than 5min; 5. Informed consent and voluntary participation of patients and their families.

Exclusion criteria

Exclusion criteria: 1. Patients who have received or will receive thrombolysis, thrombectomy or surgical treatment for this substroke; 2. Patients with subarachnoid hemorrhage; 3. Known contraindications for enhanced hypertension (such as severe stenosis of the great arteries of the cranial and cervical regions, moyamoya disease, idiopathic arteritis, high heart valve stenosis, etc.); 4. Acute stroke secondary to intracranial structural abnormalities (such as arteriovenous malformations, intracranial aneurysms, craniocerebral trauma, etc.); 5. Patients with unstable vital signs who need vasoactive drugs and may die in the acute phase; 6. Patients with diseases affecting movement, sensation and cognition [Mini-Mental State Examination (MMSE) score =4 mg/dL; 8. Patients participating in other clinical trials at the same time. 9. Patients with poor compliance or who are likely to miss follow-up.

Design outcomes

Primary

Measure	Time frame
Modified Rankin Scale;	—

Secondary

Measure	Time frame
accuracy;Achievement rate of blood pressure control;Data collection efficiency;	—

Countries

China

Contacts

Public ContactChang Hong

Xuanwu Hospital, Capital Medical University

zimu1022@126.com+86 13701034090

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026